Introduction:
Globally, PTB is a significant concern for ill health. According to
World Health Organization (WHO), Tuberculosis (TB) remains a major
threat to public health, with an estimated 10 million diagnosed cases in
2018 with stable cases in the next recent years and an estimated 1.5
million TB-related deaths in 2018 [1]. PTB is a chronic disease of
the lungs that can disseminate in various organs along with rare
complications that can be life-threatening, such as pulmonary embolism
[2]. The association of pulmonary embolism with Tuberculosis was
first reported in an observational study by Morgan in 1950 in which the
incidence of PE associated with active TB was 23.4% compared to 23.1%
of PE cases in entire series of 634 autopsies [2]. A disease like
PTB, which is prevailing for many centuries, can easily be overlooked
due to the ongoing COVID 19 pandemic and its apprehension in the
community.
Keywords : Pulmonary Tuberculosis, Pulmonary embolism,
Thromboembolism, COVID 19, SARS- CoV-2, Anti-coagulation.